 BOSTON--BUSINESS WIRE--Ikena Oncology, Inc. Ikena, a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced the pricing of its initial public offering of 7,812,500 shares of common stock at a public offering price of 16.00 per share. The shares are expected to begin trading on the Nasdaq Global Market on March 26, 2021 under the ticker symbol IKNA. The gross proceeds of the offerin 